274 related articles for article (PubMed ID: 16322336)
61. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance.
Müller CG; Bayley TA; Harrison JE; Tsang R
Thyroid; 1995 Apr; 5(2):81-7. PubMed ID: 7647577
[TBL] [Abstract][Full Text] [Related]
62. Relationship between bone turnover biomarkers, mandibular bone mineral density, and systemic skeletal bone mineral density in premenopausal and postmenopausal Indian women.
Makker A; Singh MM; Mishra G; Singh BP; Jain GK; Jadhav S
Menopause; 2012 Jun; 19(6):642-9. PubMed ID: 22240638
[TBL] [Abstract][Full Text] [Related]
63. [Bone density in differentiated cancer of the thyroid gland treated by hormone-suppressive therapy. Study based on 51 cases].
Eulry F; Bauduceau B; Lechevalier D; Magnin J; Crozes P; Flageat J; Gautier D
Rev Rhum Mal Osteoartic; 1992 Apr; 59(4):247-52. PubMed ID: 1496271
[TBL] [Abstract][Full Text] [Related]
64. Bone mineral density in postmenopausal women treated with L-thyroxine.
Adlin EV; Maurer AH; Marks AD; Channick BJ
Am J Med; 1991 Mar; 90(3):360-6. PubMed ID: 2003518
[TBL] [Abstract][Full Text] [Related]
65. Bone mineral density in women with sarcoidosis.
Sipahi S; Tuzun S; Ozaras R; Calis HT; Ozaras N; Tuzun F; Karayel T
J Bone Miner Metab; 2004; 22(1):48-52. PubMed ID: 14691687
[TBL] [Abstract][Full Text] [Related]
66. L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history.
La Vignera S; Vicari E; Tumino S; Ciotta L; Condorelli R; Vicari LO; Calogero AE
Minerva Ginecol; 2008 Dec; 60(6):475-84. PubMed ID: 18981975
[TBL] [Abstract][Full Text] [Related]
67. [Prolonged suppressive L-thyroxine therapy. Longitudinal study of the effect of LT4 on bone mineral density and bone metabolism markers in 71 patients].
Rachedi F; Rohmer V; Six P; Duquenne M; Wion Barbot N; Minebois A; Bigorgne JC; Audran M
Presse Med; 1999 Feb; 28(7):323-9. PubMed ID: 10083873
[TBL] [Abstract][Full Text] [Related]
68. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine.
Stall GM; Harris S; Sokoll LJ; Dawson-Hughes B
Ann Intern Med; 1990 Aug; 113(4):265-9. PubMed ID: 2375563
[TBL] [Abstract][Full Text] [Related]
69. Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study.
Wang S; Wang Y; Zhu L; He L; Lv M; Zhang H; Wang H; Zhang F; Lai Y; Li Y; Shan Z; Teng W
Endocrine; 2023 Jan; 79(1):113-124. PubMed ID: 36089636
[TBL] [Abstract][Full Text] [Related]
70. The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma.
Moon JH; Kim KM; Oh TJ; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
J Clin Endocrinol Metab; 2017 Jan; 102(1):78-85. PubMed ID: 27754806
[TBL] [Abstract][Full Text] [Related]
71. Bone mass after long-term euthyroidism in former hyperthyroid women treated with (131)I influence of menopausal status.
Serraclara A; Jódar E; Sarabia F; Hawkins F
J Clin Densitom; 2001; 4(3):249-55. PubMed ID: 11740067
[TBL] [Abstract][Full Text] [Related]
72. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
[TBL] [Abstract][Full Text] [Related]
73. Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism.
Tauchmanovà L; Nuzzo V; Del Puente A; Fonderico F; Esposito-Del Puente A; Padulla S; Rossi A; Bifulco G; Lupoli G; Lombardi G
Maturitas; 2004 Jul; 48(3):299-306. PubMed ID: 15207896
[TBL] [Abstract][Full Text] [Related]
74. [Does L-thyroxine administration in a dose to suppress TSH secretion induce metabolic bone disturbance in patients with thyroid carcinoma?].
Sugino K; Kure Y; Ozaki O; Ito K; Matsumoto A
Nihon Geka Gakkai Zasshi; 1992 Jul; 93(7):753-6. PubMed ID: 1508139
[TBL] [Abstract][Full Text] [Related]
75. Estimation of central osteopenia in children with chronic polyarthritis treated with glucocorticoids.
Kotaniemi A; Savolainen A; Kautiainen H; Kröger H
Pediatrics; 1993 Jun; 91(6):1127-30. PubMed ID: 8502514
[TBL] [Abstract][Full Text] [Related]
76. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature.
Quan ML; Pasieka JL; Rorstad O
J Surg Oncol; 2002 Jan; 79(1):62-9; discussion 69-70. PubMed ID: 11754378
[TBL] [Abstract][Full Text] [Related]
77. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
Hermus AR; Smals AG; Swinkels LM; Huysmans DA; Pieters GF; Sweep CF; Corstens FH; Kloppenborg PW
J Clin Endocrinol Metab; 1995 Oct; 80(10):2859-65. PubMed ID: 7559865
[TBL] [Abstract][Full Text] [Related]
78. Effect of replacement doses of thyroxine on bone mineral density.
Hanna FW; Pettit RJ; Ammari F; Evans WD; Sandeman D; Lazarus JH
Clin Endocrinol (Oxf); 1998 Feb; 48(2):229-34. PubMed ID: 9579237
[TBL] [Abstract][Full Text] [Related]
79. The effect of suppressive thyroxine therapy in nodular goiter in postmenopausal women and 2 year's bone mineral density change.
Chen CY; Chen ST; Huang BY; Hwang JS; Lin JD; Liu FH
Endocr J; 2018 Nov; 65(11):1101-1109. PubMed ID: 30158361
[TBL] [Abstract][Full Text] [Related]
80. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation.
Gyulai L; Bauer M; Garcia-Espana F; Hierholzer J; Baumgartner A; Berghöfer A; Whybrow PC
J Affect Disord; 2001 Oct; 66(2-3):185-91. PubMed ID: 11578671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
